CLINICAL_TRIALS
trial_result
· 2023-07-20
Clinical Trial Update: AFM13 in Relapsed/Refractory Cutaneous Lymphomas [Phase 1, Phase 2]
Summary
Phase 1/2 trial updates for AFM13 in relapsed/refractory cutaneous T-cell lymphoma have been completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ahmed Sawas | Conditions: Lymphoma, T-Cell, Cutaneous | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-07-20